glp-1 receptor brain Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes Study identifies gut-brain-immune network influencing
Description
In the phase 3 ACHIEVE-3 trial , adults with type 2 diabetes inadequately controlled by metformin were randomized to receive orforglipron or oral semaglutide (7 mg and 14 mg, doses approved for type 2 diabetes)
As of 2023, there are no peer-reviewed, randomised controlled trials published in reputable medical journals that demonstrate berberine patches achieve clinically meaningful systemic absorption or produce therapeutic effects comparable to oral formulations
Pharmacist.com
According to the World Health Organization, 1 in 8 people live with obesity worldwide
Nevertheless, factors such as supply challenges, restricted funding, high out-of-pocket costs and side effect fears could limit the uptake of the drugs, creating uncertainties around the future size and shape of demand
